印度 Alembic 制药公司周三公布，受美国市场强劲销售的推动，其第二季度利润增长了 81%，这推动其股价飙升了 20%。
India's Alembic Pharmaceuticals posted an 81% rise in second-quarter profit on Wednesday, helped by strong sales in the US market, sending its shares surging 20%.
该公司报告称，在截至 9 月 30 日的季度中，合并利润达到 33.5 亿卢比（合 3537 万美元），而去年同期为 18.5 亿卢比。营业收入增长超过 36%，达到 260.3 亿卢比。莫蒂拉尔奥斯瓦尔（Motilal Oswal）的分析师此前预计，Alembic 在美国仿制药业务的增长将由面临有限竞争的产品发布来推动。“我们的美国业务表现优异，这得益于强劲的销量增长和新产品的推出，同时印度市场也恢复了增长势头，”董事总经理普拉纳夫·阿明（Pranav Amin）表示。
Alembic 的美国制剂业务同比增长了 77%，而印度品牌业务增长了 14%。其原料药业务的收入增长了 39%
The company reported a consolidated profit of 3.35 billion rupees ($35.37 million) for the quarter ended September 30, up from 1.85 billion rupees a year earlier Revenue from operations rose more than 36% to 26.03 billion rupees Analysts at Motilal Oswal expected growth in Alembic's US generics segment to be driven by product launches that face limited competition "Our US business delivered an exceptional performance, driven by strong volume growth and new launches, while India regained momentum," Managing Director Pranav Amin said Alembic's US formulations business grew 77% year-on-year, while India branded business rose 14% Revenue from its active pharmaceutical ingredient segment grew 39%